Intellia Therapeutics reported a quarterly loss of $0.8 per share, matching the Zacks Consensus estimate (vs. a $0.99 loss a year ago). The sequential improvement versus last year is modest, with no apparent surprise versus expectations.
Intellia Therapeutics reported a quarterly loss of $0.8 per share, matching the Zacks Consensus estimate (vs. a $0.99 loss a year ago). The sequential improvement versus last year is modest, with no apparent surprise versus expectations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
